Synjardy 12.5 mg/1 (Empagliflozin and Metformin Hydrochloride TABLET) 12.5 mg/1

Synjardy 12.5 mg/1 tablets combine empagliflozin and metformin hydrochloride for managing type 2 diabetes. This oral medication supports blood sugar control as part of a broader treatment plan.

Strength

12.5 mg/1

Pack Size

1 BOTTLE in 1 CARTON (0597-0168-66) / 14 TABLET in 1 BOTTLE

Manufacturer / TM Owner

Boehringer Ingelheim Pharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Synjardy 12.5 mg/1 tablets are used to improve glycemic control in adults with type 2 diabetes. This combination medication works by enhancing the body's response to insulin and reducing glucose absorption in the kidneys. It is typically prescribed alongside diet and exercise to manage blood sugar levels effectively.

Side Effects

Common effects of Synjardy 12.5 mg/1 tablets may include urinary tract infections, nausea, and diarrhea. Some users might experience low blood sugar, especially when combined with other diabetes medications. It's important to monitor blood sugar levels regularly while using this medication.

Precautions & Warnings

Synjardy 12.5 mg/1 tablets should be used with caution in individuals with kidney problems or a history of lactic acidosis. It is essential to stay hydrated and avoid excessive alcohol consumption while taking this medication. Always consult a healthcare provider before starting or stopping any medication.

Avoid Interactions

Synjardy 12.5 mg/1 tablets may interact with certain medications, including other diabetes drugs, diuretics, and some antibiotics. Alcohol and certain pain medications can also affect the efficacy and safety of this medication. Always inform your healthcare provider about all medications you are taking.

Frequently Asked Questions

Synjardy 12.5 mg/1 tablets are used to improve blood sugar control in adults with type 2 diabetes.

Synjardy 12.5 mg/1 tablets are taken orally, typically with meals, as directed by a healthcare provider.

Common side effects may include urinary tract infections, nausea, and diarrhea.

Synjardy 12.5 mg/1 may interact with other medications, so it's important to consult a healthcare provider before combining it with other drugs.

Synjardy 12.5 mg/1 should be used with caution in individuals with kidney problems or a history of lactic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.